Track record · closed signal

Innoviva Inc (INVA) — closed signal from March 17, 2026

Near target Published before the outcome was known, scored automatically when the window closed on June 15, 2026 — +0.5% at the close.

Predicted vs. what happened

INVA price · publication thesis → realized outcomesplit-adjusted

$21.70 – $22.60Entry zone — fair-value band

$22.31Published — price the day we called it

$24.54Target — the price the thesis aimed for

$24.45Peak — highest point inside the window, not a realized return

$22.42Window close — end-of-window price, context only

What happened

Near target

Came within reach: 96% of the predicted growth at its peak, just short of the target.

At window close

+0.5%

realized, from the publication price to the last close inside the window

Peak gain

+9.6%

peak, from the publication price — not a realized return

S&P 500, same window

+12.8%

SPY over the identical days, dividend-adjusted

Window close

$22.42

last close inside the window, ended June 15, 2026

Peak price

$24.45

peak on April 20, 2026 — not a realized return

Days to target

—

The thesis — published March 17, 2026

Predicted growth

+10%

over the measurement window

Target price

$24.54

the price the thesis aimed for

Entry zone

$21.70 – $22.60

the fair-value band we waited for

Price at publication

$22.31

published March 17, 2026

Confidence

63%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Innoviva looks like a solid smaller biotech: it is buying back shares and building an infectious-disease business. Analysts and company updates are positive. But the stock trades very thinly, which can make buying or selling risky for short-term users. Interesting idea, but not the best choice for short-term action.

Primary drivers

Share buybacks and growth plan boost the company's outlook
Analyst comments give useful outside validation
Stronger balance sheet than many small biotech peers
Very light trading can make buying or selling unreliable

How it played out

INVA: the thesis nearly reached its target

Lyra published INVA at $22.31 with an expected gain of 10% and a $24.54 target. The thesis pointed to share buybacks, an infectious-disease growth plan, positive analyst comments, and a stronger balance sheet. It also warned that light trading could make short-term transactions unreliable.

The price rose to $24.45 on April 20, a peak gain of 9.6%. It stayed below the target and ended the window at $22.42. The expected rise largely occurred, but the stated target was never reached. The thesis partially played out.

What happened during the window

On May 6, Innoviva reported its first-quarter 2026 financial results and highlighted recent company progress. On June 1, it announced that management would participate in healthcare investor conferences during June.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All INVA signals